Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development.

Cells
Xinpei CiYuzhuo Wang

Abstract

Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. It develops mainly via NE transdifferentiation of prostate adenocarcinoma in response to androgen receptor (AR)-inhibition therapy. The study of NEPC development has been hampered by a lack of clinically relevant models. We previously established a unique and first-in-field patient-derived xenograft (PDX) model of adenocarcinoma (LTL331)-to-NEPC (LTL331R) transdifferentiation. In this study, we applied conditional reprogramming (CR) culture to establish a LTL331 PDX-derived cancer cell line named LTL331_CR_Cell. These cells retain the same genomic mutations as the LTL331 parental tumor. They can be continuously propagated in vitro and can be genetically manipulated. Androgen deprivation treatment on LTL331_CR_Cells had no effect on cell proliferation. Transcriptomic analyses comparing the LTL331_CR_Cell to its parental tumor revealed a profound downregulation of the androgen response pathway and an upregulation of stem and basal cell marker genes. The transcriptome of LTL331_CR_Cells partially resembles that of post-castrated LTL331 xenografts in mice. Notably, when grafted under the renal capsules of male NOD/SCID mice, LTL331_CR_Cells spontaneously ...Continue Reading

References

Jan 5, 2002·Differentiation; Research in Biological Diversity·Y WangG Cunha
Jan 12, 2005·The Journal of Urology·R E Sobel, M D Sadar
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Jul 6, 2010·Nucleic Acids Research·Kai WangHakon Hakonarson
Dec 23, 2011·The American Journal of Pathology·Xuefeng LiuRichard Schlegel
Oct 30, 2012·Bioinformatics·Alexander DobinThomas R Gingeras
Nov 22, 2012·Proceedings of the National Academy of Sciences of the United States of America·Frank A SuprynowiczRichard Schlegel
Dec 18, 2014·Genome Biology·Michael I LoveSimon Anders
Apr 11, 2015·Clinical Epigenetics·Pier-Luc ClermontCheryl D Helgason
Aug 4, 2015·Cell Reports·Shusuke AkamatsuColin C Collins
Aug 19, 2015·Breast Cancer Research and Treatment·Daniel D BrownPriscilla F McAuliffe
Nov 9, 2015·Differentiation; Research in Biological Diversity·Yuzhuo WangJun Pang
Feb 9, 2016·Nature Medicine·Himisha BeltranFrancesca Demichelis
Jan 25, 2017·Cancer·Tanios Bekaii-Saab, Bassel El-Rayes
May 17, 2017·Clinical Genitourinary Cancer·Emanuele ZaffutoPierre I Karakiewicz
Oct 27, 2017·PloS One·Brian BushnellEsther Singer
Dec 8, 2017·Molecular Cancer·Alexandra BorodovskyCelina M D'Cruz
Mar 8, 2018·Scientific Reports·Bruna R S CorreaSeema Agarwal
May 12, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael L BeshiriKathleen Kelly
Jul 10, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rahul AggarwalEric J Small
Oct 7, 2018·Cold Spring Harbor Perspectives in Medicine·Jia J Li, Michael M Shen
Oct 21, 2018·Genome Research·Anand MayakondaH Phillip Koeffler
Jan 19, 2019·Nature Communications·Haiyang GuoHousheng Hansen He
May 8, 2019·Proceedings of the National Academy of Sciences of the United States of America·Wassim AbidaCharles L Sawyers
Aug 1, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Himisha BeltranPeter S Nelson
Aug 2, 2019·The Journal of Biological Chemistry·Jinsong WeiBing Zhao
Sep 17, 2019·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Vincenza ConteducaHimisha Beltran
Oct 24, 2019·Archives of Pathology & Laboratory Medicine·Jing HuJiaoti Huang
Feb 23, 2020·The Prostate·Anna M GleaveYuzhuo Wang
Mar 11, 2020·Nature Reviews. Clinical Oncology·Álvaro Quintanal-VillalongaCharles M Rudin

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE149091

Methods Mentioned

BETA
xenograft
X-ray
RNA-seq
targeted gene mutation

Software Mentioned

ANNOVAR
GSEA
Genome Analysis Toolkit ( GATK )
DESeq2
maftools
R
Python
STAR aligner
BBtools

Related Concepts

Related Feeds

Cell Fate Conversion By mRNA

mRNA-based technology is being studied as a potential technology that could be used to reprogram cell fate. This technique provides the potential to generate safe reprogrammed cells that can be used for clinical applications. Here is the latest research on cell fate conversion by mRNA.

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.